Svetlovska D, Mardiak J, Kristova V
National Cancer Institute, Bratislava, Slovakia.
Bratisl Lek Listy. 2007;108(2):100-3.
Four large randomized trials to assess efficacy and toxicity of trastuzumab in adjuvant systemic therapy of breast cancer have been initiated. Results clearly demonstrate, that adjuvant treatment of trastuzumab significantly improves outcomes for women with HER2 positive breast cancer. The clinically most significant adverse events of trastuzumab are serious-infusion related reactions and cardiotoxicity. Benefit for patient should be considered according to advantage versus risk (Tab. 1, Fig. 2, Ref. 17) Full Text (Free, PDF) www.bmj.sk.
已经启动了四项大型随机试验，以评估曲妥珠单抗在乳腺癌辅助全身治疗中的疗效和毒性。结果清楚地表明，曲妥珠单抗辅助治疗可显著改善HER2阳性乳腺癌女性的预后。曲妥珠单抗临床上最显著的不良事件是严重的输液相关反应和心脏毒性。应根据获益与风险来考虑对患者的益处（表1、图2、参考文献17）全文（免费，PDF）www.bmj.sk 。
